Aion Therapeutic (XCNQ:AION) Debt-to-Asset : 0.35 (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Debt-to-Asset?

Aion Therapeutic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.04 Mil. Aion Therapeutic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Aion Therapeutic's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was C$5.89 Mil. Aion Therapeutic's debt to asset for the quarter that ended in Jan. 2024 was 0.35.

Aion Therapeutic Debt-to-Asset Historical Data

The historical data trend for Aion Therapeutic's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Debt-to-Asset Chart

Aion Therapeutic Annual Data

Trend

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Debt-to-Asset

Get a 7-Day Free Trial

0.29

0.35

4.51

3.92

Aion Therapeutic Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															1.49	3.92	6.66	3.15	0.35

Competitive Comparison of Aion Therapeutic's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Debt-to-Asset falls into.

Aion Therapeutic Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Aion Therapeutic's Debt-to-Asset for the fiscal year that ended in Apr. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.826	+	0)	/	0.211
	=	3.91

Aion Therapeutic's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.035	+	0)	/	5.888
	=	0.35

Aion Therapeutic (XCNQ:AION) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Aion Therapeutic Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aion Therapeutic (XCNQ:AION) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ANTCF:USA

Address

700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8

Website

https://www.aiontherapeutic.com

Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery.

Executives

Ismail Abdul Fattah

Director or Senior Officer of 10% Security Holder

Aion Therapeutic (XCNQ:AION) Headlines

No Headlines